Hai Pan, Sciwind Biosciences CEO

On a quest to chal­lenge No­vo Nordisk in obe­si­ty, transpa­cif­ic start­up picks up $70M — and a pair of sea­soned ex­ecs

Four years af­ter start­ing Terns Phar­ma­ceu­ti­cals to­geth­er in search of an elu­sive NASH win, Wei­dong Zhong and Mar­ti­jn Fe­naux are re­unit­ing at a new start­up.

On pa­per, Sci­wind Bio­sciences — which just raised $70 mil­lion in Se­ries C cash — em­ploys a sim­i­lar set­up as Terns: Both have em­braced the transpa­cif­ic mod­el, tak­ing root in Chi­na but plant­i­ng flags in the US.

Zhong was tapped to be pres­i­dent of the San Fran­cis­co-based sub­sidiary back in Ju­ly, on top of as­sum­ing the role as chief strat­e­gy of­fi­cer. Weeks lat­er, Fe­naux has been ap­point­ed SVP, non­clin­i­cal de­vel­op­ment and trans­la­tion­al sci­ence at the par­ent com­pa­ny out of Hangzhou — join­ing the team along­side chief sci­en­tif­ic of­fi­cer Xin­le Wu, who brings ex­pe­ri­ence run­ning R&D for both Eli Lil­ly and Am­gen in Chi­na.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.